Shanghai Haohai Biological's H1 Profit Falls on Lower Revenue

MT Newswires Live

Aug 25

Shanghai Haohai Biological Technology (HKG:6826, SHA:688366) reported an attributable profit of 211.07 million yuan for the first half of 2025, down from 235.28 million yuan a year earlier, according to an Aug. 22 Hong Kong bourse filing.

Hong Kong-listed shares of the ophthalmic products manufacturer gained over 1% in Monday afternoon trade.

Earnings per share came in at 0.91 yuan, compared with 1.01 yuan in the prior-year period.

Revenue declined to 1.29 billion yuan from 1.40 billion yuan.

The board declared an interim dividend of 0.40 yuan per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2562721151"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562721151\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562721151?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 16:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562721151","market":"us","top_or_hot":-1,"title":"Shanghai Haohai Biological's H1 Profit Falls on Lower Revenue","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SHBTF\">Shanghai Haohai Biological</a> Technology (HKG:6826, SHA:688366) reported an attributable profit of 211.07 million yuan for the first half of 2025, down from 235.28 million yuan a year earlier, according to an Aug. 22 Hong Kong bourse filing.</p><p>Hong Kong-listed shares of the ophthalmic products manufacturer gained over 1% in Monday afternoon trade.</p><p>Earnings per share came in at 0.91 yuan, compared with 1.01 yuan in the prior-year period.</p><p>Revenue declined to 1.29 billion yuan from 1.40 billion yuan.</p><p>The board declared an interim dividend of 0.40 yuan per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Haohai Biological's H1 Profit Falls on Lower Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Haohai Biological's H1 Profit Falls on Lower Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-25 16:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SHBTF\">Shanghai Haohai Biological</a> Technology (HKG:6826, SHA:688366) reported an attributable profit of 211.07 million yuan for the first half of 2025, down from 235.28 million yuan a year earlier, according to an Aug. 22 Hong Kong bourse filing.</p><p>Hong Kong-listed shares of the ophthalmic products manufacturer gained over 1% in Monday afternoon trade.</p><p>Earnings per share came in at 0.91 yuan, compared with 1.01 yuan in the prior-year period.</p><p>Revenue declined to 1.29 billion yuan from 1.40 billion yuan.</p><p>The board declared an interim dividend of 0.40 yuan per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688366","symbol_name":"昊海生科","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562721151","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562721151","pubTimestamp":1756109988,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Haohai Biological Technology  reported an attributable profit of 211.07 million yuan for the first half of 2025, down from 235.28 million yuan a year earlier, according to an Aug. 22 Hong Kong bourse filing.Hong Kong-listed shares of the ophthalmic products manufacturer gained over 1% in Monday afternoon trade.Earnings per share came in at 0.91 yuan, compared with 1.01 yuan in the prior-year period.Revenue declined to 1.29 billion yuan from 1.40 billion yuan.The board declared an interim dividend of 0.40 yuan per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"688366":"昊海生科","06826":"昊海生物科技"},"translate_title":"上海昊海生物上半年利润因收入下降而下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688366":0.9,"06826":0.9},"content_text":"Shanghai Haohai Biological Technology (HKG:6826, SHA:688366) reported an attributable profit of 211.07 million yuan for the first half of 2025, down from 235.28 million yuan a year earlier, according to an Aug. 22 Hong Kong bourse filing.Hong Kong-listed shares of the ophthalmic products manufacturer gained over 1% in Monday afternoon trade.Earnings per share came in at 0.91 yuan, compared with 1.01 yuan in the prior-year period.Revenue declined to 1.29 billion yuan from 1.40 billion yuan.The board declared an interim dividend of 0.40 yuan per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}